These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 1054729)

  • 1. Response to influenza vaccine in adjuvant 65-4.
    Smith JW; Fletcher WB; Peters M; Westwood M; Perkins FJ
    J Hyg (Lond); 1975 Apr; 74(2):251-9. PubMed ID: 1054729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A graded-dose study of inactivated, surface antigen influenza B vaccine in volunteers: reactogenicity, antibody response and protection to challenge virus infection.
    Goodeve A; Potter CW; Clark A; Jennings R; Schild GC; Yetts R
    J Hyg (Lond); 1983 Feb; 90(1):107-15. PubMed ID: 6822725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coadministration of orally inhaled zanamivir with inactivated trivalent influenza vaccine does not adversely affect the production of antihaemagglutinin antibodies in the serum of healthy volunteers.
    Webster A; Boyce M; Edmundson S; Miller I
    Clin Pharmacokinet; 1999; 36 Suppl 1():51-8. PubMed ID: 10429840
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of avian influenza A/Anhui/01/2005(H5N1) vaccine with MF59 adjuvant: a randomized clinical trial.
    Belshe RB; Frey SE; Graham IL; Anderson EL; Jackson LA; Spearman P; Edupuganti S; Mulligan MJ; Rouphael N; Winokur P; Dolor RJ; Woods CW; Walter EB; Chen WH; Turley C; Edwards KM; Creech CB; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1420-8. PubMed ID: 25291578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [On the antigenicity of influenza virus aluminum oxide adjuvant vaccine "Alorbat" in man (author's transl)].
    Desselberger U; Pressler K; Erdmann G
    Zentralbl Bakteriol Orig A; 1975 Jul; 232(2-3):160-77. PubMed ID: 1179878
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Carbohydrate fatty acid monosulphate esters are safe and effective adjuvants for humoral responses.
    Hilgers LAT; Platenburg PPLI; Bajramovic J; Veth J; Sauerwein R; Roeffen W; Pohl M; van Amerongen G; Stittelaar KJ; van den Bosch JF
    Vaccine; 2017 May; 35(24):3249-3255. PubMed ID: 28479181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody responses and resistance to challenge in volunteers vaccinated with live attenuated, detergent split and oil adjuvant A2-Hong Kong-68 (H 3 N 2 ) influenza vaccines. A report to the Medical Research Council Committee on Influenza and other Respiratory Virus Vaccines.
    Freestone DS; Hamilton-Smith S; Schild GC; Buckland R; Chinn S; Tyrrell DA
    J Hyg (Lond); 1972 Sep; 70(3):531-43. PubMed ID: 4506997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of repeated annual influenza vaccination on antibody responses against unchanged vaccine antigens in elderly frail institutionalized volunteers.
    Iorio AM; Camilloni B; Basileo M; Neri M; Lepri E; Spighi M
    Gerontology; 2007; 53(6):411-8. PubMed ID: 17975317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antibody response in man to Hong Kong influenza following 1967 formula influenza vaccine in adjuvant 65.
    Woodhour AF; McAleer WJ; Friedman A; Weibel RE; Stokes J; Hilleman MR
    Proc Soc Exp Biol Med; 1969 Jun; 131(2):501-6. PubMed ID: 5787131
    [No Abstract]   [Full Text] [Related]  

  • 10. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial.
    Mulligan MJ; Bernstein DI; Winokur P; Rupp R; Anderson E; Rouphael N; Dickey M; Stapleton JT; Edupuganti S; Spearman P; Ince D; Noah DL; Hill H; Bellamy AR;
    JAMA; 2014 Oct; 312(14):1409-19. PubMed ID: 25291577
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Madin-Darby canine kidney cell culture derived influenza A/H5N1 vaccine: a phase I trial in Taiwan.
    Pan SC; Kung HC; Kao TM; Wu H; Dong SX; Hu MH; Chou AH; Chong P; Hsieh SM; Chang SC
    J Microbiol Immunol Infect; 2013 Dec; 46(6):448-55. PubMed ID: 23022464
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunization with trivalent inactivated influenza vaccine in partially immunized toddlers.
    Englund JA; Walter EB; Gbadebo A; Monto AS; Zhu Y; Neuzil KM
    Pediatrics; 2006 Sep; 118(3):e579-85. PubMed ID: 16950949
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose ranging of adjuvant and antigen in a cell culture H5N1 influenza vaccine: safety and immunogenicity of a phase 1/2 clinical trial.
    Keitel W; Groth N; Lattanzi M; Praus M; Hilbert AK; Borkowski A; Tsai TF
    Vaccine; 2010 Jan; 28(3):840-8. PubMed ID: 19835829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative trial of influenza vaccines. I. Immunogenicity of whole virus and split product vaccines in man.
    Barry DW; Mayner RE; Staton E; Dunlap RC; Rastogi SC; Hannah JE; Blackburn RJ; Nortman DF; Graze PR
    Am J Epidemiol; 1976 Jul; 104(1):34-46. PubMed ID: 947145
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Influenza vaccination. The importance of antigen amount and adjuvant with reference to the humoral antibody formation after influenza vaccination. A comparative double-blind study with various vaccines].
    Sarateanu DE; Ehrengut W
    Fortschr Med; 1981 Sep; 99(34):1348-52. PubMed ID: 7026399
    [No Abstract]   [Full Text] [Related]  

  • 16. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WRL 105 strain live attenuated influenza vaccine; comparison of one and two dose schedules.
    Evans AE; Letley E; Ferris RD; Freestone DS
    J Hyg (Lond); 1976 Dec; 77(3):327-32. PubMed ID: 1069813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High titre neutralising antibodies to influenza after oral tablet immunisation: a phase 1, randomised, placebo-controlled trial.
    Liebowitz D; Lindbloom JD; Brandl JR; Garg SJ; Tucker SN
    Lancet Infect Dis; 2015 Sep; 15(9):1041-1048. PubMed ID: 26333337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Topical imiquimod before intradermal trivalent influenza vaccine for protection against heterologous non-vaccine and antigenically drifted viruses: a single-centre, double-blind, randomised, controlled phase 2b/3 trial.
    Hung IF; Zhang AJ; To KK; Chan JF; Li P; Wong TL; Zhang R; Chan TC; Chan BC; Wai HH; Chan LW; Fong HP; Hui RK; Kong KL; Leung AC; Ngan AH; Tsang LW; Yeung AP; Yiu GC; Yung W; Lau JY; Chen H; Chan KH; Yuen KY
    Lancet Infect Dis; 2016 Feb; 16(2):209-18. PubMed ID: 26559482
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A new surface-antigen-adsorbed influenza virus vaccine. II. Studies in a volunteer group.
    Potter CW; Jennings R; McLaren C; Edey D; Stuart-Harris CH; Brady M
    J Hyg (Lond); 1975 Dec; 75(3):353-62. PubMed ID: 1059705
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.